Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
roxithromycin, Quantity: 150 mg
Arrotex Pharmaceuticals Pty Ltd
Roxithromycin
Tablet, film coated
Excipient Ingredients: hyprolose; purified talc; maize starch; glucose; colloidal anhydrous silica; sodium starch glycollate type A; sodium starch glycollate type B; titanium dioxide; hypromellose; magnesium stearate; povidone; propylene glycol; poloxamer
Oral
10 tablets
(S4) Prescription Only Medicine
Adults: Roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: Upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. Lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. Skin and skin structure infections. Nongonococcal urethritis. Children: ROXITHROMYCIN 150 mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible microorganisms: Acute pharyngitis. Acute tonsillitis, impetigo. Appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. Therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.
Visual Identification: White to off-white, round, convex film coated tablets.; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2008-04-10